

PEDIATRICS®

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Emergency Contraception

COMMITTEE ON ADOLESCENCE

Pediatrics 2012;130;1174; originally published online November 26, 2012;

DOI: 10.1542/peds.2012-2962

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/130/6/1174.full.html>

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2012 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™





POLICY STATEMENT

Emergency Contraception

abstract

FREE

Despite significant declines over the past 2 decades, the United States continues to have teen birth rates that are significantly higher than other industrialized nations. Use of emergency contraception can reduce the risk of pregnancy if used up to 120 hours after unprotected intercourse or contraceptive failure and is most effective if used in the first 24 hours. Indications for the use of emergency contraception include sexual assault, unprotected intercourse, condom breakage or slippage, and missed or late doses of hormonal contraceptives, including the oral contraceptive pill, contraceptive patch, contraceptive ring (ie, improper placement or loss/expulsion), and injectable contraception. Adolescents younger than 17 years must obtain a prescription from a physician to access emergency contraception in most states. In all states, both males and females 17 years or older can obtain emergency contraception without a prescription. Adolescents are more likely to use emergency contraception if it has been prescribed in advance of need. The aim of this updated policy statement is to (1) educate pediatricians and other physicians on available emergency contraceptive methods; (2) provide current data on safety, efficacy, and use of emergency contraception in teenagers; and (3) encourage routine counseling and advance emergency-contraception prescription as 1 part of a public health strategy to reduce teen pregnancy. This policy focuses on pharmacologic methods of emergency contraception used within 120 hours of unprotected or underprotected coitus for the prevention of unintended pregnancy. Emergency contraceptive medications include products labeled and dedicated for use as emergency contraception by the US Food and Drug Administration (levonorgestrel and ulipristal) and the “off-label” use of combination oral contraceptives. *Pediatrics* 2012;130:1174–1182

BACKGROUND

Despite significant declines over the past 2 decades, the United States continues to have teen birth rates that are significantly higher than other industrialized nations.^{1,2} The most recent birth data available indicate a birth rate of 34.3 per 1000 among 15- to 19-year-olds.³ The most current pregnancy outcomes data indicate that 57% of teen pregnancies ended in live births, 27% ended in induced abortion, and 16% ended in miscarriage or stillbirth.^{4,5} Pediatricians have an important role, through their interactions with adolescents, to address the major public health objective of continuing to reduce adolescent pregnancy in the United States.⁶

COMMITTEE ON ADOLESCENCE

KEY WORDS

emergency contraception, adolescents, teen pregnancy, birth control, oral contraceptives

ABBREVIATIONS

FDA—US Food and Drug Administration

STI—sexually transmitted infection

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

All policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

www.pediatrics.org/cgi/doi/10.1542/peds.2012-2962

doi:10.1542/peds.2012-2962

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2012 by the American Academy of Pediatrics

The current decrease in teen pregnancies since the 1990s has resulted from both increased abstinence and increased use of contraception,^{7,8} but large numbers of teenagers continue to engage in unprotected sexual activity. The rate of “ever having intercourse” among 15- to 19-year-old females is 43%, and, among males of the same age range, this rate is 42%.⁹ The rate increases between early and late adolescence, from 13% of 15-year-olds to 70% of 19-year-olds. Although most teenagers report first intercourse with a steady partner and consensual sex, approximately 10% report being forced to have sex. Rates of sexual assault among teenagers and young adults are higher than in any other group,¹⁰ another factor increasing the risk of unintended pregnancy.¹¹

Nearly 80% of pregnancies in adolescents are unintended¹² and result from contraceptive failure or nonuse. The most commonly used method of contraception reported by teenagers who have had intercourse is the condom, followed by withdrawal and the oral contraceptive pill.⁹ Research has shown, however, that many teenagers use contraceptive methods inconsistently.¹³ In addition to the risk of sexually transmitted infections (STIs), the pregnancy rate for withdrawal is particularly high (27% of women who use the withdrawal method will have an unintended pregnancy in the first year of using this method).¹⁴ Although condoms are important for protection against STIs as well as pregnancy and the pill can be a very effective method for pregnancy prevention, both methods require strict adherence by the user to be maximally effective.

Emergency contraception can reduce the risk of pregnancy if used up to 120 hours after unprotected intercourse^{15,16} or contraceptive failure and is most effective if used in the first 24 hours.^{17,18}

In August 2007, the US Food and Drug Administration (FDA) authorized non-prescription access to Plan B (levonorgestrel, manufactured by Teva Women’s Health, Woodcliff Lake, NJ) for women 18 years of age and older and then in 2009 changed the age limit to females 17 years of age and older. Prescription for emergency contraception is required for teenagers younger than 17 years in most states.¹⁹ As of the date of publication, males 17 years or older can also access Plan B with or without a prescription.

Studies have shown that adolescents are more likely to use emergency contraception if it has been prescribed in advance of need.²⁰ However, a majority of practicing pediatricians and pediatric residents do not routinely counsel patients about emergency contraception and have not prescribed it.^{21–24} This policy statement will focus on pharmacologic methods of emergency contraception used within 120 hours of unprotected or under-protected coitus for the prevention of unintended pregnancy (Table 1).

DEFINITION OF EMERGENCY CONTRACEPTION

Emergency contraception is the only contraceptive method designed to prevent pregnancy after intercourse. Indications for use of emergency contraception include sexual assault, unprotected vaginal sexual intercourse, and contraceptive failures, such as broken condoms and missed or late doses of other hormonal methods (ie, missing 3 consecutive doses of active birth control pills, patch off for more than 24 hours during ‘patch-on’ week, or vaginal ring out for more than 3 hours during ‘ring-in’ week). Emergency contraceptive medications include products labeled and approved for use as emergency contraception by the FDA (levonorgestrel

and ulipristal acetate) and the “off-label” use of combination oral contraceptives—the Yuzpe method—described in the literature since 1974.²⁵ Pediatricians should also be aware that insertion of a copper intrauterine device within 5 days of unprotected intercourse is an additional method of emergency contraception available in the United States. This statement does not cover the intrauterine device method in more detail, because it is not an option available to most pediatricians in their offices.

EMERGENCY-CONTRACEPTION METHODS

Progestin-Only Regimens

Levonorgestrel emergency contraception was approved by the FDA in 1999 under the brand name Plan B and is currently marketed as Plan B, Plan B One Step (Teva Women’s Health, Woodcliff Lake, NJ), and Next Choice (Watson Pharma Inc, Corona, CA). Plan B and Next Choice consist of 2 pills containing 0.75 mg of levonorgestrel each. Although prescribing directions indicate that patients should take each of the 2 pills 12 hours apart, recent data suggest that both pills taken together as a single dose (total treatment dose of 1.5 mg levonorgestrel) is equally effective and without increased adverse effect.¹⁵ To this effect, the next generation of emergency contraception, Plan B One Step, is packaged as a single pill with 1.5 mg levonorgestrel to be taken 1 time.²⁶ Pharmacies may stock both 0.75-mg and 1.5-mg levonorgestrel versions. Package labeling indicates that all 3 brands of levonorgestrel emergency contraception should be taken within 72 hours of unprotected intercourse; however, data support that use up to 120 hours after intercourse may prevent pregnancy.^{15,16}

TABLE 1 Selected Regimens for Emergency Contraception Available in the United States^{14,72}

Brand	First Dose	Second Dose	Ethinyl Estradiol per Dose, µg	Levonorgestrel per Dose, mg
Progestin-only pills				
Next Choice or Plan B	2 pills	None	0	1.5
Plan B One-Step	1 pill	None	0	1.5
Ovrette	20 pills	20 pill	0	0.75
Other emergency contraception				
ella	30 mg of ulipristal acetate			
Combined estrogen and progestin pills				
Ovral	2 white pills	2 white pills	100	0.5
Levora	4 white pills	4 white pills	120	0.6
Nordette	4 light orange pills	4 light orange pills	120	0.6
Seasonale	4 pink pills	4 pink pills	120	0.6
Triphasil	4 yellow pills	4 yellow pills	120	0.5
Alesse	5 pink pills	5 pink pills	120	0.5

Additional combinations are available at: <http://ec.princeton.edu>.

The FDA-labeled levonorgestrel methods are currently the preferred emergency contraception for teenagers because of their improved adverse effect profile and increased effectiveness in comparison with combination oral contraceptive methods. Adolescents should be instructed to take 1.5 mg of levonorgestrel as soon as possible and up to 120 hours after unprotected intercourse. No physical examination or pregnancy testing is required before use. Adolescents are advised to have a pregnancy test done if they do not have a normal period within 3 weeks of emergency-contraception use.

Ulipristal Acetate Progesterone Agonist/Antagonist

In August 2010, the FDA approved a progesterone agonist/antagonist ulipristal acetate (ella, Watson Pharma Inc, Corona, CA) for use as an emergency contraceptive.²⁷ Ulipristal binds to the human progesterone receptor, thereby preventing the binding of progesterone. Ulipristal is a single pill containing 30 mg of ulipristal acetate and is indicated up to 120 hours after unprotected intercourse.²⁸ Unlike with hormonal emergency contraception, existing pregnancy must

be excluded before prescribing ulipristal because of the risk of fetal loss if used in the first trimester of pregnancy.²⁸ Patients should be counseled that a pregnancy test is indicated if their period is more than 7 days later than expected after taking ulipristal. Patients should also be instructed to return for evaluation of the rare but possible occurrence of ectopic pregnancy if severe abdominal pain occurs 3 to 5 weeks after the dose. Ulipristal is available only by prescription regardless of age.

Combined Hormonal Regimens (Yuzpe Method)

The use of combination oral contraceptives for emergency contraception is commonly referred to as the "Yuzpe method."²⁵ Commonly used since 1974, its acceptability and efficacy was limited by adverse effects of nausea and vomiting. The Yuzpe method involves taking 2 doses of pills, each containing a minimum of 100 µg of ethinyl estradiol and a minimum of 500 µg of levonorgestrel. Levonorgestrel is the active isomer of norgestrel, so equivalent dosing of any pill containing norgestrel requires doubling the dose of progestin. Other pill formulations used for emergency

contraception are included in Table 1. Similar information is available from the Office of Population Research at Princeton University, which maintains a comprehensive source of information on emergency contraception (<http://ec.princeton.edu/>). The availability of many combination oral contraceptives with norgestrel or levonorgestrel makes this alternative particularly helpful when there is no or limited access to an emergency-contraception product. Although combination oral contraceptives have not been labeled specifically for emergency contraception, the FDA Reproductive Health Advisory Committee and professional organizations such as the American College of Obstetricians and Gynecologists have declared the use of combination oral contraceptives safe and effective for emergency contraception.^{29,30}

MECHANISM OF ACTION

Hormonal emergency contraception, including combined and progestin-only methods, inhibits ovulation, disrupts follicular development, and interferes with the maturation of the corpus luteum.^{31–37} These are the same mechanisms by which other hormonal methods of contraception prevent pregnancy. Results of studies evaluating the effect of hormonal emergency contraception on the endometrium are conflicting. Some studies suggest that endometrial histologic or biochemical alterations occur after emergency contraception by which endometrial receptivity to the implantation of a fertilized egg is impaired.^{31,38,39} Other studies demonstrate little to no effect on the endometrium.^{32,33,35,37,40,41} Suggested mechanisms, including alteration of sperm or egg transport, interference with the fertilization process, and/or cervical mucus changes, have not been verified by clinical data.^{42,43} Hormonal emergency

contraception does not interrupt established pregnancies and has not been linked to teratogenic effects.^{44–47}

Ulipristal acetate inhibits follicular development and rupture, so its primary mechanism of action as an emergency contraceptive is considered to be inhibition or delay of ovulation.²⁸ It also decreases endometrial thickness and may have a direct effect on implantation. Ulipristal is in pregnancy category X, because data from animal studies suggest that fetal loss is a risk of use during the first trimester. Therefore, pregnancy should be excluded before a dose is given.

EFFICACY

The efficacy of combined hormonal or progestin-only emergency contraception depends on the timing of use within the menstrual cycle.^{48,49} A randomized controlled trial has shown that the progestin-only method, Plan B, is more effective at preventing pregnancy than combination hormone methods. When the 2 regimens were started within 72 hours, the overall pregnancy rate was 1.1% in the levonorgestrel-only group in comparison with 3.2% in the combination oral contraceptive (Yuzpe method) group.¹⁷ The proportion of pregnancies prevented in this study was 85% with levonorgestrel and 57% with the combination oral contraceptive (Yuzpe) method in comparison with the expected number when no treatment was given. The effectiveness of emergency contraception might be summarized as follows: if 100 female adolescents have unprotected coitus in the middle of their menstrual cycles, estimates suggest that approximately 8 will become pregnant. Appropriate use of emergency contraception would reduce this number to approximately 2 pregnancies.¹⁴

Compared with 1.5 mg of levonorgestrel, ulipristal acetate has been shown to be equally efficacious when taken

within 72 hours of unprotected intercourse. Glasier and colleagues⁵⁰ observed no statistically significant difference in pregnancy rates between women taking 30 mg of ulipristal (1.8%) or 1.5 mg of levonorgestrel (2.6%) within 72 hours of unprotected intercourse (odds ratio, 0.69%; 95% confidence interval, 0.35–1.31). This finding was consistent with a previous study.⁵¹ Between 72 and 120 hours, the Glasier study showed some evidence that ulipristal may be more effective at preventing pregnancy.

ADVERSE EFFECTS AND CONTRAINDICATIONS

Levonorgestrel-Only Methods (Plan B, Plan B One Step, and Next Choice)

The only contraindication to use of levonorgestrel emergency contraception is known pregnancy because of lack of utility, not concern for teratogenicity or fetal loss. Young women with contraindications to estrogen may use levonorgestrel. The rate of nausea and vomiting with levonorgestrel emergency contraception is approximately half that with the combination oral contraceptive (Yuzpe) method, and routine use of antiemetics is not indicated.¹⁷ Package labeling for the newest levonorgestrel emergency-contraception product, Plan B One Step, indicates that the most common adverse effect reported after use was heavier menstrual bleeding.²⁶ Repeated use of levonorgestrel emergency contraception is associated with the same adverse effects as 1-time use. A recent Cochrane review of the subject found no serious adverse effects in trials of repeated use.⁵²

Ulipristal

The most common adverse effects reported by users of ulipristal include headache (18%), nausea (12%), and abdominal pain (12%).²⁸ As previously noted, animal studies suggest that

fetal loss is a risk of use during the first trimester. No fetal malformations have been reported.²⁸ It is recommended to redose ulipristal if vomiting occurs within 3 hours of the initial dose.

Yuzpe/Estrogen-Containing Methods

The most common adverse effects that occur during the first 24 to 48 hours of using estrogen-containing emergency-contraception methods are nausea (approximately 50%) and vomiting (approximately 20%), which seem unaffected by food intake.^{53–55} Other adverse effects might include fatigue, breast tenderness, headache, abdominal pain, and dizziness.¹⁴ The severity and incidence of nausea and vomiting can be decreased significantly by using an antiemetic 1 hour before an estrogen-containing regimen.⁵⁵ Antiemetics are ineffective if taken after nausea is present.⁵⁵ Effective oral antiemetics include meclizine, 25 to 50 mg, and metoclopramide, 10 mg by mouth, taken once before combination-hormone methods.^{55,56} Patients with contraindications to estrogen use such as history of thromboembolism should not use the combination oral contraceptive (Yuzpe) method.

OTHER CLINICAL CONSIDERATIONS

The discussion of emergency-contraception methods with patients must also include the fact that none of these methods will protect from STIs. Patients should be encouraged to contact their physician after use to schedule follow-up visits for STI testing or treatment, as indicated. In addition, these follow-up visits are an important time to discuss options for ongoing contraception, abstinence, and consensual intercourse. It should be emphasized to patients that emergency contraception is intended for emergency use and that routine use of

emergency contraception to prevent pregnancy is not as effective as the regular use of other forms of contraception. Although emergency contraception is exclusively for use by females, young men should be counseled on this method so that they may also suggest use to their female partners if needed.

ADOLESCENTS AND EMERGENCY CONTRACEPTION: AWARENESS AND ACCESS

The regulatory changes and public discourse surrounding emergency contraception have increased the public's awareness of the methods; however, large numbers of teenagers still do not have much knowledge about correct use. In 2002, Aiken and colleagues⁵⁷ reassessed the awareness and knowledge of emergency contraception among 13- to 21-year-old females recruited from the same Pittsburgh clinic and drug treatment center from which they recruited participants for a 1996 study of emergency-contraception knowledge. Their study showed that, in 2002, 73% of teenagers were aware of emergency contraception, an increase from 44% in 1996. Although 95% of teenagers who were aware also knew where to get emergency contraception in 2002, up from 78% in 1996, only 52% were aware of the correct time frame for use (up from only 20% in 1996). Recent studies conducted in New York City and Hawaii found the percentage of teenagers aware of emergency contraception was closer to 50%.^{58,59}

Data from the most recent 2006–2008 National Survey of Family Growth indicate that 14% of sexually experienced adolescent girls have ever used emergency contraception,⁹ up from 8% in the 2002 survey. Reasons for use of emergency contraception by teenagers were examined by Alford et al⁶⁰ in

a retrospective cohort study published in 2010. The most common reason for use was condom failure. Importantly, 13% of adolescents' use of emergency contraception during the study period was for nonconsensual penetration. A qualitative study conducted in Philadelphia aimed to explore teenagers' attitudes about the use of emergency contraception in more detail. Themes that emerged as barriers to emergency contraception use among the teenagers included worries about confidentiality, ability to get emergency contraception depending on age, worries about adverse effects, and lack of transportation to obtain the medication.⁶¹ In a recent study of college-aged students, fewer than 16% knew that emergency contraception was available in their college health center.⁶²

One important strategy to increase timely access to emergency contraception for adolescent girls is advanced prescribing. Advanced prescription for emergency contraception means providing a teenager with a supply or a prescription for emergency contraception before it is needed. Advanced prescribing facilitates access for teenagers in states that require prescriptions and also reduces the cost of obtaining emergency contraception for adolescents of all ages whose insurance provides coverage for emergency contraception with a prescription. In a 2010 review of 7 randomized trials of emergency contraception that included teenagers, it was shown that advanced prescription increased the use of emergency contraception and decreased time to use.²⁰ None of the studies showed an increase in sexual activity or decrease in ongoing contraceptive use in adolescents given advanced access to emergency contraception.

Despite evidence that improved access to emergency contraception (through advanced prescribing and allowing

nonprescription access) increases the likelihood of use, no studies have demonstrated that improved access to emergency contraception reduces the pregnancy rate in a population.^{63,64} There may be statistical reasons for this related to sample size of the studies, but it also may be that pregnancy rates remain unchanged overall because unprotected intercourse remains more frequent than emergency contraceptive use, despite increased access. The lack of demonstrated population level impact does not negate the potential for the method to reduce the risk of unintended pregnancy for an individual woman, however.

ETHICAL DILEMMAS FOR PHYSICIANS AND PHARMACISTS

Despite multiple studies showing no increased risk behavior and evidence that hormonal emergency contraception will not disrupt an established pregnancy, public and medical discourse reflects that personal values of physicians and pharmacists continue to affect emergency-contraception access, particularly for adolescents.^{65–70} Some physicians refuse to provide emergency contraception to teenagers, regardless of the circumstance, and others may provide emergency contraception only if nonconsensual penetration has occurred. Both of these choices by physicians have important adverse consequences for adolescents in their ability to access emergency contraception.

A study published in 2009 demonstrated that the decision to provide emergency contraception at a time of need but not in advance of need may be related to the physician's beliefs about whether it is okay for teenagers to have sex.²⁴ Often, physicians hold conflicting values when approaching reproductive health issues with teenagers. Physicians may object to

unprotected intercourse or intercourse outside of marriage, but they may also feel the need to prevent teen pregnancy. Pediatricians should strive to be aware of the ways in which the underlying beliefs they bring to their clinical practice affect the care that they provide.

The American Academy of Pediatrics has issued a policy statement on refusal to provide information or treatment on the basis of conscience.⁷¹ According to the policy, pediatricians have a duty to inform their patients about relevant, legally available treatment options to which they object and have a moral obligation to refer patients to other physicians who will provide and educate about those services. Failure to inform/educate about availability and access to emergency-contraception services violates this duty to their adolescent and young adult patients.

SUMMARY AND RECOMMENDATIONS

1. Pediatricians should be aware that sexual behavior is prevalent among teenagers and that as many as 10% of sexually active teenagers may be the victims of sexual assault.
2. Effective contraceptive use with dual methods (condoms in addition to hormonal contraception/intrauterine device) or abstinence are the best ways for teenagers to avoid pregnancy. Many teenagers are at high risk of contraceptive failure, however, and emergency contraception is an important backup method for all teenagers. Emergency contraception is most effective in decreasing risk of pregnancy when used as soon as possible, but it may be used 120 hours after unprotected or under-protected intercourse.
3. Indications for use of emergency contraception include sexual assault, -unprotected intercourse, condom breakage or slippage, and missed or late doses of hormonal contraceptives, including the oral contraceptive pill, contraceptive patch, contraceptive ring, and injectable contraception.
4. Pediatricians should provide levonorgestrel 1.5 mg (Plan B, Plan B One Step, or Next Choice) for teenagers in immediate need of emergency contraception and provide prescriptions/supply for teenagers to have on hand in case of future need (ie, advanced provision). No pregnancy test is required before the use of levonorgestrel.
5. The levonorgestrel method has an improved adverse effect profile and increased effectiveness compared with combined hormonal emergency-contraception methods. The rate of nausea and vomiting with levonorgestrel emergency contraception is approximately half that with the combination oral contraceptive (Yuzpe) method, and routine use of antiemetics is not indicated. Advanced provision increases the likelihood that teenagers will use emergency contraception when needed, reduces the time to use, and does not decrease condom or other contraceptive use. Both males and females 17 years or older may obtain levonorgestrel without a prescription, but must show proof of age.
6. Other emergency-contraception methods include ulipristal (ella) and estrogen-containing (Yuzpe) emergency-contraception methods. Adverse effects of ulipristal include headache, nausea, and abdominal pain. Existing pregnancy must be excluded before prescribing ulipristal. The adverse effects of the estrogen-containing emergency contraception (Yuzpe) method include nausea, vomiting, and abdominal pain. Patients with contraindications to estrogen use, such as history of thromboembolism, should not use the combination oral contraceptive (Yuzpe) method.
7. All adolescents, males and females, and families of disabled adolescents should be counseled on emergency contraception as part of routine anticipatory guidance in the context of a discussion on sexual safety and family planning regardless of current intentions for sexual behavior. All contraceptive and STI counseling for adolescents should include education and counseling regarding the use and availability and advance prescription of emergency contraception wherever these visits occur, including emergency departments, clinics, and hospitals. Adolescents should be instructed to use emergency contraception as soon as possible after unprotected intercourse and to then schedule a follow-up appointment with their primary provider to address the need for STI testing and ongoing contraception.
8. At the policy level, pediatricians should advocate for increased non-prescription access to emergency contraception for teenagers regardless of age and for insurance coverage of emergency contraception to reduce cost barriers.

LEAD AUTHORS

Krishna K. Upadhyya, MD, MPH
Cora C. Breuner, MD, MPH

CONTRIBUTING AUTHOR

Maria E. Trent, MD, MPH

COMMITTEE ON ADOLESCENCE, 2010–2011

Margaret J. Blythe, MD, Chairperson
William P. Adelman, MD
Cora C. Breuner, MD, MPH

David A. Levine, MD
Arik V. Marcell, MD, MPH
Pamela J. Murray, MD, MPH
Rebecca F. O'Brien, MD
Warren M. Seigel, MD

LIAISONS

Rachel Miller, MD – *American College of Obstetricians and Gynecologists*
Jorge L. Pinzon, MD – *Canadian Pediatric Society*

Benjamin Shain, MD, PhD – *American Academy of Child and Adolescent Psychiatry*

STAFF

Karen Smith
Mark Del Monte, JD

REFERENCES

1. Singh S, Darroch JE. Adolescent pregnancy and childbearing: levels and trends in developed countries. *Fam Plann Perspect*. 2000;32(1):14–23
2. Darroch JE, Frost JJ, Singh S, and the Study Team. *Teenage Sexual and Reproductive Behavior in Developed Countries: Can More Progress Be Made?* Occasional Report No. 3. New York, NY: Alan Guttmacher Institute; 2001
3. Hamilton BE, Ventura SJ. Birth Rates for U.S. Teenagers Reach Historic Lows for All Age and Ethnic Groups. NCHS data brief, no 89. Hyattsville, MD: National Center for Health Statistics; 2012
4. Ventura SJ, Curtin SC, Abma JC, Henshaw SK. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990–2008. *Natl Vital Stat Rep*. 2012;60(7):1–21
5. Kost K, Henshaw S. *U.S. Teenage Pregnancies, Births and Abortions, 2008: National Trends by Race and Ethnicity*. New York, NY: Guttmacher Institute; 2012. Available at: www.guttmacher.org/pubs/USTPtrends08.pdf. Accessed August 23, 2012
6. US Department of Health and Human Services. Healthy People 2020 Topics and Objectives: family planning. Available at: www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=13. Accessed February 9, 2012
7. Santelli JS, Lindberg LD, Finer LB, Singh S. Explaining recent declines in adolescent pregnancy in the United States: the contribution of abstinence and improved contraceptive use. *Am J Public Health*. 2007;97(1):150–156
8. Centers for Disease Control and Prevention. Trends in the prevalence of sexual behaviors: National YRBS: 1991–2009. Available at: www.cdc.gov/HealthyYouth/yrbs/pdf/us_sexual_trend_yrbs.pdf. Accessed October 15, 2012
9. Martinez G, Copen CE, Abma JC. Teenagers in the United States: sexual activity, contraceptive use and childbearing, 2006–2010 national survey of family growth. *Vital Health Stat 23*. 2011;(31):1–35
10. US Department of Justice. Questions and answers: domestic violence, sexual assault, teen dating violence, and stalking. Available at: www.ovv.usdoj.gov/docs/qa-factsheet.pdf. Accessed February 9, 2012
11. Trent M, Clum G, Roche KM. Sexual victimization and reproductive health outcomes in urban youth. *Ambul Pediatr*. 2007;7(4):313–316
12. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. *Perspect Sex Reprod Health*. 2006;38(2):90–96
13. Woods JL, Shew ML, Tu W, Ofner S, Ott MA, Fortenberry JD. Patterns of oral contraceptive pill-taking and condom use among adolescent contraceptive pill users. *J Adolesc Health*. 2006;39(3):381–387
14. Hatcher RA, Trussell J, Stewart F, et al. *Contraceptive Technology*. 19th ed. New York, NY: Ardent Media; 2007
15. von Hertzen H, Piaggio G, Ding J, et al; WHO Research Group on Post-ovulatory Methods of Fertility Regulation. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. *Lancet*. 2002;360(9348):1803–1810
16. Rodrigues I, Grou F, Joly J. Effectiveness of emergency contraceptive pills between 72 and 120 hours after unprotected sexual intercourse. *Am J Obstet Gynecol*. 2001;184(4):531–537
17. Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. *Lancet*. 1998;352(9126):428–433
18. Piaggio G, von Hertzen H, Grimes DA, Van Look PF. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. *Lancet*. 1999;353(9154):721
19. Guttmacher Institute. State policies in brief: emergency contraception as of February 1, 2012. Available at: www.guttmacher.org/statecenter/spibs/spib_EC.pdf. Accessed February 9, 2012
20. Meyer JL, Gold MA, Haggerty CL. Advance provision of emergency contraception among adolescent and young adult women: a systematic review of literature. *J Pediatr Adolesc Gynecol*. 2011;24(1):2–9
21. Sills MR, Chamberlain JM, Teach SJ. The associations among pediatricians' knowledge, attitudes, and practices regarding emergency contraception. *Pediatrics*. 2000;105(4 pt 2):954–956
22. Golden NH, Seigel WM, Fisher M, et al. Emergency contraception: pediatricians' knowledge, attitudes, and opinions. *Pediatrics*. 2001;107(2):287–292
23. Lim SW, Iheagwara KN, Legano L, Coupey SM. Emergency contraception: are pediatric residents counseling and prescribing to teens? *J Pediatr Adolesc Gynecol*. 2008;21(3):129–134
24. Upadhyia KK, Trent ME, Ellen JM. Impact of individual values on adherence to emergency contraception practice guidelines among pediatric residents: implications for training. *Arch Pediatr Adolesc Med*. 2009;163(10):944–948
25. Yuzpe AA, Thurlow HJ, Ramzy I, Leyshon JL. Post coital contraception—A pilot study. *J Reprod Med*. 1974;13(2):53–58
26. US Food and Drug Administration. Plan B One Step prescribing information. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2009/0219981bl.pdf. Accessed February 9, 2012
27. US Food and Drug Administration. FDA approves ella tablets for prescription emergency contraception. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm222428.htm. Accessed February 9, 2012
28. US Food and Drug Administration. ella (ulipristal acetate) tablet prescribing information. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2010/022474s0001bl.pdf. Accessed February 9, 2012
29. US Food and Drug Administration. Prescription drug products; certain combined oral contraceptives for use as postcoital emergency contraception. *Fed Regist*. 1997;62(37):8609
30. American College of Obstetricians and Gynecologists. ACOG practice bulletin No. 112: emergency contraception. *Obstet Gynecol*. 2010;115(5):1100–1109

31. Ling WY, Wrixon W, Acorn T, Wilson E, Collins J. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. III. Effect of preovulatory administration following the luteinizing hormone surge on ovarian steroidogenesis. *Fertil Steril*. 1983;40(5):631–636
32. Landgren BM, Johannisson E, Aedo AR, Kumar A, Shi YE. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology. *Contraception*. 1989;39(3):275–289
33. Swahn ML, Westlund P, Johannisson E, Bygdeman M. Effect of post-coital contraceptive methods on the endometrium and the menstrual cycle. *Acta Obstet Gynecol Scand*. 1996;75(8):738–744
34. Hapangama D, Glasier AF, Baird DT. The effects of peri-ovulatory administration of levonorgestrel on the menstrual cycle. *Contraception*. 2001;63(3):123–129
35. Durand M, del Carmen Cravioto M, Raymond EG, et al. On the mechanisms of action of short-term levonorgestrel administration in emergency contraception. *Contraception*. 2001;64(4):227–234
36. Croxatto HB, Fuentealba B, Brache V, et al. Effects of the Yuzpe regimen, given during the follicular phase, on ovarian function. *Contraception*. 2002;65(2):121–128
37. Marions L, Hultenby K, Lindell I, Sun X, Ståbi B, Gemzell Danielsson K. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. *Obstet Gynecol*. 2002;100(1):65–71
38. Kubba AA, White JO, Guillebaud J, Elder MG. The biochemistry of human endometrium after two regimens of postcoital contraception: a dl-norgestrel/ethinylestradiol combination or danazol. *Fertil Steril*. 1986;45(4):512–516
39. Rowlands S, Kubba AA, Guillebaud J, Bounds W. A possible mechanism of action of danazol and an ethinylestradiol/norgestrel combination used as postcoital contraceptive agents. *Contraception*. 1986;33(6):539–545
40. Taskin O, Brown RW, Young DC, Poindexter AN, Wiehle RD. High doses of oral contraceptives do not alter endometrial alpha 1 and alpha v beta 3 integrins in the late implantation window. *Fertil Steril*. 1994;61(5):850–855
41. Gemzell-Danielsson K. Mechanism of action of emergency contraception. *Contraception*. 2010;82(5):404–409
42. Glasier A. Emergency postcoital contraception. *N Engl J Med*. 1997;337(15):1058–1064
43. Croxatto HB, Devoto L, Durand M, et al. Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature. *Contraception*. 2001;63(3):111–121
44. Zhang L, Chen J, Wang Y, Ren F, Yu W, Cheng L. Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study. *Hum Reprod*. 2009;24(7):1605–1611
45. Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. *Obstet Gynecol*. 1995;85(1):141–149
46. Bracken MB. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies. *Obstet Gynecol*. 1990;76(3 pt 2):552–557
47. Simpson JL, Phillips OP. Spermicides, hormonal contraception and congenital malformations. *Adv Contracept*. 1990;6(3):141–167
48. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. *N Engl J Med*. 1995;333(23):1517–1521
49. Wilcox AJ, Dunson D, Baird DD. The timing of the “fertile window” in the menstrual cycle: day specific estimates from a prospective study. *BMJ*. 2000;321(7271):1259–1262
50. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. *Lancet*. 2010;375(9714):555–562
51. Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. *Obstet Gynecol*. 2006;108(5):1089–1097
52. Halpern V, Raymond EG, Lopez LM. Repeated use of pre- and postcoital hormonal contraception for prevention of pregnancy. *Cochrane Database Syst Rev*. 2010;(1):CD007595
53. Ellertson C, Webb A, Blanchard K, et al. Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. *Obstet Gynecol*. 2003;101(6):1160–1167
54. Percival-Smith RK, Abercrombie B. Post-coital contraception with dl-norgestrel/ethinyl estradiol combination: six years experience in a student medical clinic. *Contraception*. 1987;36(3):287–293
55. Raymond EG, Creinin MD, Barnhart KT, Lovvorn AE, Rountree RW, Trussell J. Meclizine for prevention of nausea associated with use of emergency contraceptive pills: a randomized trial. *Obstet Gynecol*. 2000;95(2):271–277
56. Ragan RE, Rock RW, Buck HW. Metoclopramide pretreatment attenuates emergency contraceptive-associated nausea. *Am J Obstet Gynecol*. 2003;188(2):330–333
57. Aiken AM, Gold MA, Parker AM. Changes in young women’s awareness, attitudes, and perceived barriers to using emergency contraception. *J Pediatr Adolesc Gynecol*. 2005;18(1):25–32
58. Ahern R, Frattarelli LA, Delto J, Kaneshiro B. Knowledge and awareness of emergency contraception in adolescents. *J Pediatr Adolesc Gynecol*. 2010;23(5):273–278
59. New York City Department of Health and Mental Hygiene. *Teen Pregnancy in New York City: 1997-2007*. New York, NY: New York City Department of Health and Mental Hygiene; 2009
60. Alford SM, Lappin RE, Wells K, Barone AR, Dalton VK. Adolescent and young adult women’s use of emergency contraception. *J Pediatr Adolesc Gynecol*. 2010;23(5):279–284
61. Mollen CJ, Barg FK, Hayes KL, Gotcsik M, Blades NM, Schwarz DF. Assessing attitudes about emergency contraception among urban, minority adolescent girls: an in-depth interview study. *Pediatrics*. 2008;122(2). Available at: www.pediatrics.org/cgi/content/full/122/2/e395
62. Miller LM. College student knowledge and attitudes toward emergency contraception. *Contraception*. 2011;83(1):68–73
63. Raymond EG, Stewart F, Weaver M, Monteith C, Van der Pol B. Impact of increased to emergency contraceptive pills: a randomized controlled trial. *Obstet Gynecol*. 2006;108(5):1098–1106
64. Raymond EG, Trussell J, Polis CB. Population effect of increased access to emergency contraceptive pills: a systematic review. *Obstet Gynecol*. 2007;109(1):181–188
65. Conard LA, Fortenberry JD, Blythe MJ, Orr DP. Pharmacists’ attitudes toward and practices with adolescents. *Arch Pediatr Adolesc Med*. 2003;157(4):361–365
66. Grimes DA. Emergency contraception: politics trumps science at the U.S. Food and Drug Administration. *Obstet Gynecol*. 2004;104(2):220–221
67. Pruitt SL, Mullen PD. Contraception or abortion? Inaccurate descriptions of emergency contraception in newspaper articles, 1992-2002. *Contraception*. 2005;71(1):14–21

68. Simonds W, Ellertson C. Emergency contraception and morality: reflections of health care workers and clients. *Soc Sci Med.* 2004;58(7):1285–1297
69. Karasz A, Kirchen NT, Gold M. The visit before the morning after: barriers to pre-prescribing emergency contraception. *Ann Fam Med.* 2004;2(4):345–350
70. Fairhurst K, Wyke S, Ziebland S, Seaman P, Glasier A. “Not that sort of practice”: the views and behaviour of primary care practitioners in a study of advance provision of emergency contraception. *Fam Pract.* 2005;22(3):280–286
71. Committee on Bioethics. Policy statement—physician refusal to provide information or treatment on the basis of claims of conscience. *Pediatrics.* 2009;124(6):1689–1693
72. Princeton Office of Population Affairs. Which birth control pills can be used for emergency contraception in the United States? Available at: <http://ec.princeton.edu/questions/dose.html#dose>. Accessed February 9, 2012

Emergency Contraception
COMMITTEE ON ADOLESCENCE

Pediatrics 2012;130;1174; originally published online November 26, 2012;
DOI: 10.1542/peds.2012-2962

Updated Information & Services	including high resolution figures, can be found at: http://pediatrics.aappublications.org/content/130/6/1174.full.html
References	This article cites 57 articles, 8 of which can be accessed free at: http://pediatrics.aappublications.org/content/130/6/1174.full.html#ref-list-1
Citations	This article has been cited by 1 HighWire-hosted articles: http://pediatrics.aappublications.org/content/130/6/1174.full.html#related-urls
Post-Publication Peer Reviews (P³Rs)	One P ³ R has been posted to this article: http://pediatrics.aappublications.org/cgi/eletters/130/6/1174
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Committee on Adolescence http://pediatrics.aappublications.org/cgi/collection/committee_on_adolescence Adolescent Medicine http://pediatrics.aappublications.org/cgi/collection/adolescent_medicine
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://pediatrics.aappublications.org/site/misc/Permissions.xhtml
Reprints	Information about ordering reprints can be found online: http://pediatrics.aappublications.org/site/misc/reprints.xhtml

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2012 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

